Targeting Metabolic Dysfunction in Parkinson’s Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection

Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinson’s disease (PD), focusing on body weight regulation and neuroprotection. Recent Findings GLP-1 RAs modulate insulin signaling, reduce neuroinfl...

Descripción completa

Detalles Bibliográficos
Autores: Avilés-Olmos, I. (Iciar)|||/items/4c1cd688-4dac-40b2-be8a-a1c8c75468bf, Espinoza-Vinces, C. (Christian)|||/items/463b0ab0-d175-461c-9bef-58f6e22af1ad, Rogel-Portugal, L. (Leyre)|||/items/bc2e8053-a09a-457b-b36d-b582a4a907c1, Luquin-Piudo, M.R. (María Rosario)|||/items/6449c359-8b33-4ca4-9ff1-ca1505be7ed3
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/122211
Acceso en línea:https://hdl.handle.net/10171/122211
Access Level:acceso abierto
Palabra clave:Parkinson’s disease
GLP-1 receptor agonists
Metabolism
Body weight
Neuroprotection
Diabetes
Obesity
Descripción
Sumario:Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinson’s disease (PD), focusing on body weight regulation and neuroprotection. Recent Findings GLP-1 RAs modulate insulin signaling, reduce neuroinflammation and oxidative stress, and improve mitochondrial functional mechanisms linked to neuroprotection. Clinical trials show modest but sustained improvements in motor symptoms and suggest benefits in cognition, mood, and apathy. While GLP-1 RAs induce weight loss in diabetes, their metabolic impact in normoglycaemic PD patients appears limited. However, individuals with obesity or insulin resistance may experience enhanced clinical and cognitive outcomes. Summary GLP-1 RAs offer a multifaceted therapeutic strategy in PD, targeting both central neurodegenerative processes and peripheral metabolic dysfunction. Their potential for disease modification and symptom relief, particularly in specific phenotypes, supports their further exploration as part of a personalized treatment approach.

Similares en LA Referencia